IDEAYA’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Ideaya develops small molecule-based therapeutics for the treatment of cancer. Read more

Yujiro S. Hata's photo - CEO of IDEAYA

CEO

Yujiro S. Hata

CEO Approval Rating

81/100

Founded:

2015

Status:

PublicNASDAQIDYA

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Fortress Biotech is one of IDEAYA's top competitors. Fortress Biotech was founded in 2006 in New York, New York. Like IDEAYA, Fortress Biotech also operates in the Biotechnology industry. Fortress Biotech generates $41.4M more revenue than IDEAYA.

Mayne Pharma is a top competitor of IDEAYA. Mayne Pharma was founded in 1994, and is headquartered in Salisbury, South Australia. Like IDEAYA, Mayne Pharma also competes in the Pharmaceuticals field. Mayne Pharma generates $368.4M more revenue vs. IDEAYA.

Kineta is seen as one of IDEAYA's top competitors. Kineta is headquartered in Seattle, Washington, and was founded in 2008. Like IDEAYA, Kineta also operates in the Biotechnology field. Kineta generates ∞% the revenue of IDEAYA.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Sunesis a competitor of IDEAYA?

Quarterly and Annual Revenue

Coming soon for IDEAYA!

Annual Revenue

Acquisitions

No recent acquisitions found related to IDEAYA

IDEAYA Funding History

$17.4M$111.4M$117.1M

Since IDEAYA was founded in 2015, it has participated in 3 rounds of funding. In total IDEAYA has raised $117.1M. IDEAYA's last funding round was on May 2019 for a total of $5.8M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
May 2019
$5.8M

Series B
Jan 2018
$94M
Equity
Feb 2016
$17.4M
-

Total Funding: $117.1M

Since IDEAYA was founded in 2015, it has participated in 3 rounds of funding. In total IDEAYA has raised $117.1M. IDEAYA's last funding round was on May 2019 for a total of $5.8M

Investments

No recent investments found related to IDEAYA

IDEAYA News

August 12, 2020Medical Buyer

IDEAYA Biosciences, Inc. reports second quarter 2020 financial results and provides business update

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery a... See more »
August 4, 2020BioSpace

IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment

Collaboration, Option and License Agreement Effective following HSR Clearance and $100 Million Up-Fro... See more »
July 18, 2020Pharmabiz

IDEAYA Biosciences meets clinical protocol criteria for cohort expansion in skin melanoma for phase 2 GNAQ/11 basket trial

IDEAYA Biosciences Inc, an oncology─focused precision medicine company committed to the discovery and... See more »
July 10, 2020MarketScreener

Corporate Presentation - July 2020

(marketscreener.com) Safe Harbor Statement Certain statements in this presentation and the accompanyi... See more »
July 9, 2020MarketScreener

Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- IDEAYA Biosciences, In... See more »
June 20, 2020Zolmax News

Equities Analysts Set Expectations for IDEAYA Biosciences' Q2 2020 Earnings (NASDAQ:IDYA)

IDEAYA Biosciences (NASDAQ:IDYA) - Equities research analysts at Oppenheimer boosted their Q2 2020 EP... See more »

IDEAYA Press Releases

December 9, 2019centralcharts

Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020

IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm ... See more »
May 8, 2019PR Newswire

IDEAYA Receives Authorization to Proceed with Phase 1/2 Tissue-Type Agnostic Basket Trial to Treat Patients with Tumors Harboring GNAQ/11 Mutations and PKC Fusions

SOUTH SAN FRANCISCO, Calif., May 8, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focuse... See more »
January 2, 2019PR Newswire

IDEAYA Biosciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019

SOUTH SAN FRANCISCO, Calif., Jan. 2, 2019 /PRNewswire/ -- IDEAYA Biosciences, Inc., an oncology-focus... See more »
January 5, 2018StreetInsider

IDEAYA Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthro... See more »
September 19, 2016PR Newswire

FierceBiotech names IDEAYA Biosciences as one of its "Fierce 15" Biotech Companies of 2016

SAN FRANCISCO and SAN DIEGO, Sept. 19, 2016 /PRNewswire/ -- IDEAYA Biosciences, an oncology-focused b... See more »

IDEAYA Videos

Headquarters

7000 Shoreline Court Suite 350

South San Francisco, California94080

650-443-6209

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Ideaya develops small molecule-based therapeutics for the treatment of cancer. IDEAYA was founded in 2015. IDEAYA's headquarters is located in South San Francisco, California, USA 94080. It has raised 117.1M in 3 rounds. The latest round was in May 20...

CEO

IDEAYA's CEO, Yujiro S. Hata, currently has an approval rating of 81%. IDEAYA's primary competitors are Fortress Biotech, Mayne Pharma & Kineta.

Website

ideayabio.com

Frequently Asked Questions about IDEAYA

  1. When was IDEAYA founded?

    IDEAYA was founded in 2015
  2. Who is IDEAYA's CEO?

    IDEAYA's CEO is Yujiro S. Hata
  3. How much revenue does IDEAYA generate?

    IDEAYA generates $ < 1M in revenue
  4. How much funding does IDEAYA have?

    IDEAYA has historically raised $117.1M in funding
  1. Where is IDEAYA's headquarters?

    IDEAYA's headquarters is in South San Francisco California, USA
  2. How many employees does IDEAYA have?

    IDEAYA has 47 employees
  3. What sector does IDEAYA operate in?

    IDEAYA is in Biotechnology, Pharmaceuticals
  4. Who are IDEAYA's competitors?

    IDEAYA's top competitors are Fortress Biotech, Mayne Pharma, Kineta